Genomic, Genetic Testing, and Biomarker Literacy

Genomic, Genetic Testing, and Biomarker Literacy

The Core Distinction Patients Confuse

OCN candidates must separate two terms patients use interchangeably. Genomic (somatic) tumor testing evaluates alterations in cancer tissue or circulating tumor DNA that the tumor acquired — they are not in the patient's normal cells and are not inherited. Genetic (germline) testing evaluates inherited variants present in every normal cell and shared with relatives. A tumor BRCA1 finding on a somatic panel may or may not be germline; confirmatory germline testing is needed when criteria are met. The wording matters because implications for therapy, screening, insurance, and family communication differ.

The Genetic Information Nondiscrimination Act (GINA, 2008) bars health insurers and employers from using germline results discriminatorily, but it does not cover life, disability, or long-term-care insurance — a frequent patient question.

Common Test Methods

High-Yield Biomarker-Drug Pairings

The OCN exam rewards recognition of biomarker-targeted therapy links:

• HER2-positive breast/gastric cancer -> trastuzumab, pertuzumab (predictive).
• EGFR mutation in non-small cell lung cancer -> osimertinib; ALK or ROS1 fusion -> targeted inhibitors.
• BRAF V600E melanoma -> BRAF/MEK inhibitors.
• Microsatellite-instability-high (MSI-H) / mismatch-repair-deficient (dMMR) tumors -> checkpoint inhibitors across cancer types.
• BRCA1/2 mutation in ovarian, breast, prostate, pancreatic cancer -> PARP (poly ADP-ribose polymerase) inhibitors.

Biomarker Purposes

Biomarkers fall into five categories. Diagnostic confirms a cancer subtype. Predictive estimates likelihood of benefit from a specific drug (HER2 overexpression predicting trastuzumab benefit). Prognostic describes disease course regardless of therapy (Oncotype DX recurrence score in breast cancer). Pharmacogenomic flags metabolism or toxicity risk — for example, dihydropyrimidine dehydrogenase (DPYD) variants increase fluorouracil toxicity, and UGT1A1 affects irinotecan. Monitoring markers track response or resistance, such as serial circulating tumor DNA.

Nurses never say a biomarker guarantees response; it identifies likely options.

Germline Testing and Family Implications

Inherited pathogenic variants raise risk for specific cancers depending on the syndrome. High-yield examples:

Family-history red flags that warrant genetics referral: cancer at unusually young age, multiple relatives with related cancers, bilateral or multifocal disease, male breast cancer, ovarian or pancreatic cancer, metastatic prostate cancer, medullary thyroid cancer, numerous colon polyps, or a known familial variant. The OCN collects a three-generation pedigree when appropriate and refers; the nurse does not interpret inheritance for relatives.

Specimen and Result Literacy

Testing can fail. Decalcified bone, low tumor purity, scant tissue, old specimens, or prolonged formalin fixation degrade DNA. Liquid biopsy helps when tissue is inaccessible, but false negatives occur when tumor DNA shedding is low. Results are reported as pathogenic, likely pathogenic, variant of uncertain significance (VUS), benign, or insufficient sample. A VUS is not treated like a pathogenic variant — no prophylactic surgery or cascade testing is driven by a VUS until reclassified. Nurses teach patients not to overinterpret a portal result before provider or genetics review.

Hereditary Syndrome Counseling and Cascade Testing

When a pathogenic germline variant is confirmed, cascade testing offers single-site testing to at-risk relatives, who can then pursue enhanced surveillance or risk reduction. For example, a confirmed Lynch syndrome variant prompts earlier and more frequent colonoscopy and consideration of endometrial surveillance; a BRCA1/2 carrier may discuss earlier mammography and breast MRI, risk-reducing salpingo-oophorectomy, and chemoprevention.

The OCN reinforces that these are decisions made with a genetics professional and provider, supports the patient's autonomy in choosing whether and when to inform relatives, and addresses anxiety, guilt, and confidentiality concerns. The nurse never directly informs relatives of their risk or recommends prophylactic surgery; that is the role of genetic counseling and the care team.

RN Scope and Coordination

Within scope: explain test purpose, collection, result timing, why results change planning, and whom to call. Outside scope: classifying variants, recommending prophylactic surgery, selecting targeted therapy, or telling relatives they carry risk. The OCN coordinates outside pathology blocks, confirms whether testing was already done, tracks pending results to prevent treatment delays, and escalates when family history meets referral criteria or a patient misunderstands germline implications.

A common test trap: a tumor-only (somatic) panel is not the same as germline testing, so a patient cannot assume children are affected based on a tumor result, and a benign or VUS germline result does not justify altering screening for relatives until reclassification occurs.